We studied 36 glioblastoma cases at HC-UNICAMP from 2008 to 2012 and classified the immunohistochemical distribution of the wild-type epidermal growth factor receptor (EGFR), mutated forms of p53 protein and isocitrate dehydrogenase-1 (IDH-1) and murine double protein 2 (MDM2). Immunostaining findings were correlated with clinical data and response to treatment (surgery, chemotherapy and radiotherapy). About 97% of the tumors were primary, most of them localized in the frontal lobe. Mean time free of clinical or symptomatic disease and free time of radiological disease were 7.56 and 7.14 months, respectively. We observed a significant positive correlation between expressions of p53 and MDM2, EGFR and MDM2. Clinical, radiological and overall survivals also showed a significant positive correlation. p53 staining and clinical survival showed a significant negative correlation. The current series provides clinical and histopathological data that contribute to knowledge on glioblastoma in Brazilians. © 2015 Associacao Arquivos de Neuro-Psiquiatria. All rights reserved.737561568Wen, P.Y., Kesari, S., Malignant gliomas in adults (2008) N Engl J Med, 359 (5), pp. 492-507. , http://dx.doi.org/10.1056/NEJMra0708126Bishop, J.M., Molecular themes in oncogenesis (1991) Cell, 64 (2), pp. 235-248. , http://dx.doi.org/10.1016/0092-8674(91)90636-DLouis, D.N., Ohgaki, H., Wiestler, O.D., (2007) WHO Classification of Tumors of the Central Nervous System, pp. 33-49. , 4th Edition. Lyon: International Agency for Research on CancerPelloski, C.E., Ballman, K.V., Furth, A.F., Zhang, L., Lin, E., Sulman, E.P., Epidermal growth factor receptor variant III status defines clinically distinct subtypes of glioblastoma (2007) J Clin Oncol, 25 (16), pp. 2288-2294. , http://dx.doi.org/10.1200/JCO.2006.08.0705Collins, V.P., Mechanisms of disease: Genetic predictors of response to treatment in brain tumors (2007) Nat Clin Pract Oncol, 4 (6), pp. 362-374. , http://dx.doi.org/10.1038/ncponc0820Furnari, F.B., Fenton, T., Bachoo, R.M., Mukasa, A., Stommel, J.M., Stegh, A., Malignant astrocytic glioma: Genetics, biology, and paths to treatment (2007) Genes Dev, 21 (21), pp. 2683-2710. , http://dx.doi.org/10.1101/gad.1596707Sathornsumetee, S., Reardon, D.A., Desjardins, A., Quinn, J.A., Vredenburgh, J.J., Rich, J.N., Molecularly targeted therapy for malignant glioma (2007) Cancer, 110 (1), pp. 13-24. , http://dx.doi.org/10.1002/cncr.22741Dang, L., White, D.W., Gross, S., Bennett, B.D., Bittinger, M.A., Driggers, E.M., Cancer-associated IDH1 mutations produce 2-hydroxyglutarate (2009) Nature, 462 (7274), pp. 739-744. , http://dx.doi.org/10.1038/nature08617Smeitink, J., Metabolism, gliomas, and IDH1 (2010) N Engl J Med, 362 (12), pp. 1144-1145. , http://dx.doi.org/10.1056/NEJMcibr0912922Yan, H., Parsons, D.W., Jin, G., McLendon, R., Rasheed, B.A., Yuan, W., IDH1 and IDH2 mutations in gliomas (2009) N Engl J Med, 360 (8), pp. 765-773. , http://dx.doi.org/10.1056/NEJMoa0808710Juratli, T.A., Kirsch, M., Geiger, K., Klink, B., Leipnitz, E., Pinzer, T., The prognostic value of IDH mutations and MGMT promoter status in secpmdary high-grade gliomas (2012) J Neurooncol, 110 (3), pp. 325-333. , http://dx.doi.org/10.1007/s11060-012-0977-2Comb, S., Rieken, S., Wick, W., Abdollahi, A., Deimling, A., Debus, J., Prognostic significance of IDH-1 and MGMT in patients with glioblastoma: One step forward, and one step back? (2011) Radiat Oncol, 6 (1), p. 115. , http://dx.doi.org/10.1186/1748-717X-6-115Ohno, M., Narita, Y., Miyakita, Y., Matsushita, Y., Yoshida, A., Fukushima, S., Secondary glioblastomas with IDH1/2 mutations have longer glioma history from preceding lower-grade gliomas (2013) Brain Tumor Pathol, 30 (4), pp. 224-232. , http://dx.doi.org/10.1007/s10014-013-0140-6Giordana, M.T., Duó, D., Gasverde, S., Trevisan, E., Boghi, A., Morra, I., MDM2 overexpression is associated with short survival in adults with medulloblastoma (2002) Neuro Oncol, 4 (2), pp. 115-122. , http://dx.doi.org/10.1093/neuonc/4.2.115Korkolopoulou, P., Christodoulou, P., Kouzelis, K., Hadjiyannakis, M., Priftis, A., Stamoulis, G., MDM2 and p53 expression in gliomas: A multivariate survival analysis including proliferation markers and epidermal growth factor receptor (1997) Br J Cancer, 75 (9), pp. 1269-1278. , http://dx.doi.org/10.1038/bjc.1997.216Brandsma, D., Stalpers, L., Taal, W., Sminia, P., Van Den Bent, M.J., Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas (2008) Lancet Oncol, 9 (5), pp. 453-461. , http://dx.doi.org/10.1016/S1470-2045(08)70125-6Brem, S.S., Bierman, P.J., Black, P.H., Brem, H., Chamberlain, M.C., Chiocca, E.A., Central nervous system cancers (2008) J Natl Compr Canc Netw, 6 (5), pp. 456-504Barajas, R.F., Jr., Phillips, J.J., Parvataneni, R., Molinaro, A., Essock-Burnes, E., Bourne, G., Regional variation in histopathologic features of tumor specimens from treatment-naive glioblastoma correlates with anatomic and physiologic MR imaging (2012) Neuro-Oncol, 14 (7), pp. 942-954. , http://dx.doi.org/10.1093/neuonc/nos128Jain, R.K., Di Tomaso, E., Duda, D.G., Loeffler, J.S., Sorensen, A.G., Batchelor, T.T., Angiogenesis in brain tumours (2007) Nat Rev Neurosci, 8 (8), pp. 610-622. , http://dx.doi.org/10.1038/nrn2175Guo, P., Hu, B., Gu, W., Xu, L., Wang, D., Huang, H.J., Platelet-derived growth factor-B enhances glioma angiogenesis by stimulating vascular endothelial growth factor expression in tumor endothelia and by promoting pericyte recruitment (2003) Am J Pathol, 162 (4), pp. 1083-1093. , http://dx.doi.org/10.1016/S0002-9440(10)63905-3